Stock Report

Zynext Ventures Invests in Feldan Therapeutics to Drive Innovation in Intracellular Drug Delivery

Posted On : 2025-04-17 08:55:43( TIMEZONE : IST )

Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in Feldan Therapeutics (Feldan), a Canada-based early clinical-stage pharmaceutical company pioneering the development of treatments based on intracellular delivery of therapeutics.

Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities. The company's lead candidate, FLD-103, is administered directly into basal cell carcinoma (BCC) lesions, where the Shuttle peptide facilitates the delivery of a Hedgehog inhibitor to its target within BCC cells. This innovative approach aims to provide BCC patients with a non-surgical treatment option that improves outcomes and significantly enhances their quality of life. Additionally, Feldan is advancing a pulmonary program that leverages the Shuttle's unique ability to transport biomolecules into hard-to-deliver lung cells to address the unmet and growing medical needs of patients with respiratory diseases.

Speaking on the development, Dr. Sharvil Patel, MD of Zydus Lifesciences, said, "At Zydus, we are committed towards advancing the development of novel therapeutics to addressing critical gaps in healthcare through innovation. We are pleased to support Feldan in exploring a potentially safe and targeted option for patients with dermatological and pulmonary disease and help them lead a better quality of life."

Jay Kothari, Director of Zynext Ventures, highlighted, "Feldan's platform has the potential to transform intracellular delivery and pioneer next-generation therapeutics, aligning with the disruptive innovations we aim to add to our portfolio."

"This partnership with Zynext Ventures marks an exciting step forward in our commitment to improve patients' quality of life and address critical drug delivery challenges," said FrançoisThomas Michaud, CEO of Feldan Therapeutics. "With Zynext Ventures' strategic expertise and shared dedication to innovation, we are well-positioned to accelerate the development of next-generation therapies."

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 822.10 as compared to the previous close of Rs. 884.20. The total number of shares traded during the day was 306861 in over 19173 trades.

The stock hit an intraday high of Rs. 887.00 and intraday low of 813.00. The net turnover during the day was Rs. 255961544.00.